sponsored
PatientsVille.com Logo

PatientsVille

Mercaptopurine Medical Research Studies

Up-to-date List of Mercaptopurine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Mercaptopurine Medical Research Studies

Rank Status Study
1 Recruiting Study on Two Different Formulations of 6-Mercaptopurine. Tablet Versus Oral Liquid
Conditions: Acute Lymphoblastic Leukemia;   6-Mercaptopurine Therapy
Interventions: Drug: Xaluprine;   Drug: Puri-Nethol
Outcome Measures: Time to maximum concentration (Tmax);   Area under curve(AUC);   Maximum concentration (Cmax);   Time to half-life (T½)
2 Recruiting Comparative Pharmacokinetics of a Compounded 6-Mercaptopurine Liquid Formulation Preparation and Tablets
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: 6-Mercaptopurine
Outcome Measure: Pharmacokinetics of 6-MP
3 Recruiting A Clinical Trial in Patients With BRCA Defective Tumours
Conditions: Breast Cancer;   Ovarian Cancer
Interventions: Drug: 6-Mercaptopurine;   Drug: Methotrexate
Outcome Measure: To determine the objective response rate to 6MP/MTX in this patient population.
4 Recruiting Study Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission
Condition: Leukemia
Interventions: Behavioral: compliance monitoring;   Behavioral: telephone-based intervention;   Drug: Mercaptopurine;   Other: computer-assisted intervention;   Other: counseling intervention;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: standard follow-up care
Outcome Measures: Adherence rate to 6MP defined as the ratio of MEMS pill container openings to the number of days that 6MP doses were prescribed during each study month;   Effect of socio-demographic and clinical characteristics as well as health beliefs/knowledge on changes in adherence with the IP
5 Not yet recruiting Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: 6-thioguanine
Outcome Measures: Change in median thiopurine metabolite index;   Toxicities;   Change in median DNA-TG
6 Recruiting ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: 6MPindividualized;   Drug: 6MPfixed
Outcome Measures: Fraction of patients that become MRD-negative at treatment days 85 and/or 92 (end-of-consolidation) and event-free survival. MRD is measured either by Flow-cytometry (for PreB-ALL patients) or PCR for clonal generearrangements(for T-ALL patients);   Toxicity of treatment, degree of myelo-, hepato- and renal toxicity; and development of asparaginase antibodies.
7 Recruiting A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
Condition: Acute Lymphoblastic Leukemia (ALL)
Intervention: Drug: Allopurinol
Outcome Measures: Absolute neutrophil count;   Feasibility of the addition of allopurinol to ALL maintenance therapy;   Safety of the addition of allopurinol to ALL maintenance therapy;   Effects of allopurinol on liver function tests;   Alteration of 6-MP metabolism through the addition of allopurinol
8 Not yet recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: blinatumomab;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: methotrexate;   Drug: Mercaptopurine;   Drug: dasatinib;   Other: laboratory biomarker analysis
Outcome Measures: Overall survival (OS) (Cohort I);   Incidence of dose-limiting toxicity, defined as any grade 3-4 non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) (Cohort II);   Complete response (CR + CRi) rate (Cohort I);   Disease-free survival;   Response rates (Cohort II);   OS (Cohort II);   Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0;   MRD negativity;   Time to achieve MRD negativity
9 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: vincristine sulfate;   Drug: daunorubicin hydrochloride;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: Mercaptopurine;   Radiation: radiation therapy;   Drug: nelarabine;   Drug: doxorubicin hydrochloride;   Drug: asparaginase;   Drug: dexamethasone;   Drug: thioguanine;   Other: laboratory biomarker analysis
Outcome Measures: Event-free survival (EFS) after initial remission;   Nelarabine toxicity assessment by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Incidence of toxicities of combination chemotherapy with vs without nelarabine as assessed by NCI CTCAE version 4.0;   Efficacy of combination chemotherapy with vs without nelarabine;   Incidence of toxicities of high-dose methotrexate (with leucovorin calcium rescue) and Mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase;   Efficacy of high-dose methotrexate (with leucovorin calcium rescue) and Mercaptopurine vs escalating-dose methotrexate (without leucovorin calcium rescue) and pegaspargase;   Incidence of CNS relapse;   Overall survival
10 Not yet recruiting Adalimumab for the Management of Post-operative Crohn's Disease (CD)
Condition: Crohn Disease
Interventions: Drug: Adalimumab;   Drug: 6 Mercaptopurine
Outcome Measures: The proportion of patients with endoscopic recurrence at 12 months, as evaluated by the Rutgeerts endoscopic scoring system.;   Proportion of patients in clinical remission at 12 months as assessed by the CDAI score.
11 Recruiting Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Acute Undifferentiated Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: lestaurtinib;   Drug: cyclophosphamide;   Drug: pegaspargase;   Drug: prednisone;   Drug: methylprednisolone;   Drug: dexamethasone;   Drug: cytarabine;   Drug: methotrexate;   Biological: filgrastim;   Drug: leucovorin calcium;   Drug: etoposide;   Drug: Mercaptopurine;   Drug: vincristine sulfate;   Drug: hydrocortisone sodium succinate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Event-free survival of MLL-R infants randomized to a modified P9407 backbone with or without lestaurtinib;   Safe, tolerable, and biologically active dose of lestaurtinib as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Pharmacokinetic profile of lestaurtinib by plasma inhibitory activity (PIA) assay
12 Recruiting Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: doxorubicin hydrochloride;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: Mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: thioguanine;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
Outcome Measures: Improvement in DFS from 93% to 96% in AR patients based on the methotrexate randomization;   Determination of whether the 5-year DFS in AR patients is adversely affected by the reduced pulses in maintenance;   Determination of whether less intensive therapy will maintain DFS >= 95% for LR patients randomized to 1 of 2 low-intensity regimens;   DFS for Down syndrome patients;   Burden of therapy in AR patients overall at different time points during and at the end of therapy;   Burden of therapy in AR patients randomized to every 4-week vs every 12-week pulses during maintenance therapy
13 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Cognitive/Functional Effects;   Neurotoxicity;   Pain;   Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia;   Therapy-related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: clofarabine;   Drug: doxorubicin hydrochloride;   Drug: hydrocortisone sodium succinate;   Radiation: selective external radiation therapy;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: prednisone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: Mercaptopurine tablet;   Drug: leucovorin calcium;   Drug: thioguanine;   Drug: etoposide
Outcome Measures: Comparison of DFS of children with HR-ALL receiving post-Induction age adjusted ITT on an MBFM-IMHDM backbone compared to age adjusted IT MTX;   Comparison of DFS of children, adolescents, and young adults with VHR-ALL between arms;   Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR-ALL;   Toxicity and tolerability of arms II and III compared to arm I in patients with VHR-ALL;   Increase of greater than or equal to 65% of 5-year DFS and less than 10% induction mortality in patients with DS and HR-ALL treated with modified Induction and post-Induction therapy regimen with MBFM-IMIDM;   Toxicity and tolerability of MBFM-IMIDM in children with Down syndrome;   Percentage of VHR-ALL patients randomized to control versus experimental arms that attain MRD less than or equal to 0.01% upon recovery from consolidation;   OS rate for HR-ALL patients;   OS rate for VHR-ALL patients;   Peripheral blood absolute lymphocyte count in prediction of DFS in children, adolescents, and young adults with HR-ALL;   Incidence and prognostic significance of recently discovered recurrent genomic lesions, including high CRLF2 expression, CRLF2 activating genomic lesions, JAK mutations, and IKZF1 mutations/deletions;   Prognostic significance of molecular risk classifiers using Low Density Array (LDA) Taqman cards;   Frequency of occurrence of key adverse events across all patient subgroups of HR-ALL;   Differences in the burden of therapy between HR-ALL and VHR-ALL when treated on the various arms of this study;   Comparison of drug delivery of vincristine sulfate, pegaspargase and methotrexate during Induction, Consolidation, DI, and IM II in 16-30 year olds on the control arm of the VHR study to AYAs with ALL on the C10403 adult cooperative group trial
14 Recruiting Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Conditions: Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
Interventions: Drug: Daunorubicin;   Drug: Vincristine;   Drug: PEG-asparaginase;   Drug: Intrathecal Methotrexate;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Thioguanine
Outcome Measures: 3-Year Event-Free Survival (EFS) rate;   Efficacy Monitoring by Patient Response
15 Recruiting Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
Outcome Measures: Continuous complete remission of patients receiving high-dose and conventional dose PEG-asparaginase.;   Event-free survival;   Overall survival;   Level of minimal residual disease (MRD) on the 15th day of remission induction;   Time to CNS relapse or the last follow up since diagnosis
16 Recruiting Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Conditions: Recurrent Childhood Acute B-lymphoblastic Leukemia;   Recurrent Childhood B-lymphoblastic Lymphoma
Interventions: Drug: dexamethasone;   Drug: vincristine sulfate;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: etoposide;   Biological: aldesleukin;   Drug: pegaspargase;   Drug: methotrexate;   Drug: Mercaptopurine;   Drug: cytarabine;   Drug: mitoxantrone;   Drug: teniposide;   Drug: vinblastine;   Biological: natural killer cell infusion;   Other: laboratory biomarker analysis;   Drug: therapeutic hydrocortisone;   Procedure: allogeneic hematopoietic stem cell transplantation
Outcome Measures: 3-year overall survival rate of patients with relapsed ALL;   3-year event-free survival rates in patients with relapsed ALL;   Proportion of participants with positive minimal residual disease;   Mean of CD20 expression levels;   Median CD20 expression levels
17 Not yet recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: bortezomib;   Drug: cytarabine;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: daunorubicin hydrochloride;   Drug: pegaspargase;   Drug: methotrexate;   Drug: cyclophosphamide;   Drug: Mercaptopurine;   Drug: doxorubicin hydrochloride;   Drug: thioguanine;   Drug: hydrocortisone sodium succinate;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: etoposide;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Outcome Measures: EFS between modified ABFM backbone with or without bortezomib in all randomized patients;   EFS;   Cumulative incidence rates;   Incidence of toxicity associated with modified standard therapy, including dexamethasone and additional pegaspargase as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   EFS between VHR T-ALL patients treated with HR BFM intensification blocks who become MRD negative and those who remain MRD positive at the end of HR Block 3;   EFS between VHR T-LLy patients treated with HR BFM intensification blocks who have partial remission (PR) or complete remission (CR) with those who do not respond (NR)
18 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: dexamethasone;   Drug: methotrexate;   Drug: pegaspargase;   Drug: cyclophosphamide;   Drug: Mercaptopurine;   Biological: blinatumomab;   Drug: etoposide;   Drug: prednisone;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Outcome Measures: OS;   MRD status;   Toxicity, per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
19 Not yet recruiting Blinatumomab in Treating Younger Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: dexamethasone;   Drug: vincristine sulfate;   Drug: pegaspargase;   Drug: mitoxantrone hydrochloride;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: cytarabine;   Drug: leucovorin calcium;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: asparaginase;   Procedure: allogeneic hematopoietic stem cell transplantation;   Biological: blinatumomab;   Drug: Mercaptopurine;   Drug: thioguanine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: 2-year DFS of HR and IR relapse patients;   3-year DFS of LR relapse patients;   Rates of MRD positivity (> 0.01%);   Morphologic CR rate;   MRD negativity (< 0.01%) rate;   Proportion of patients that proceed to HSCT after treatment with blinatumomab (for treatment failure patients not previously receiving blinatumomab);   Feasibility of rapid taper of immune suppression for subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no aGVHD defined as < 25% rate of grade III-IV aGVHD;   Safety of rapid taper of immune suppression for subset of HSCT patients with MRD >= 0.01% pre- and/or post-HSCT with no aGVHD defined as < 5% rate of treatment-related mortality (TRM)
20 Recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: alemtuzumab;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: fludarabine phosphate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Drug: dexamethasone;   Drug: cyclophosphamide;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: tacrolimus;   Drug: etoposide phosphate;   Drug: cytarabine;   Drug: Mercaptopurine;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: Disease-free survival (DFS);   Probability of being BCR-ABL negative in the bone marrow and peripheral blood at the completion of the CNS prophylaxis course (restricted to those patients achieving a complete response [CR]);   Feasibility of maintenance therapy in this patient population (restricted to those patients achieving a CR);   Overall survival;   DFS;   Response

These studies may lead to new treatments and are adding insight into Mercaptopurine etiology and treatment.

A major focus of Mercaptopurine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Mercaptopurine